Discovery of small molecule PLpro inhibitor against COVID-19 using structure-based virtual screening, molecular dynamics simulation, and molecular mechanics/Generalized Born surface area (MM/GBSA) calculation

被引:0
作者
Jie Pang
Shan Gao
Zengxian Sun
Guangsheng Yang
机构
[1] Xuzhou Medical University Affiliated of Lianyungang Hospital,
来源
Structural Chemistry | 2021年 / 32卷
关键词
COVID-19; PLpro inhibitor; Virtual screening; Molecular dynamics simulation;
D O I
暂无
中图分类号
学科分类号
摘要
COVID-19 is spreading in a global pandemic that is endangering human life and health. Therefore, there is an urgent need to target COVID-19 to find effective treatments for this emerging acute respiratory infection. Viral Papain-Like cysteine protease (PLpro), similar to papain and the cysteine deubiquitinase enzyme, has been a popular target for coronavirus inhibitors, as an indispensable enzyme in the process of coronavirus replication and infection of the host. Combined structure-based virtual screening, molecular dynamics (MD) simulation, and molecular mechanics/Generalized Born surface area (MM/GBSA) free energy calculation approaches were utilized for identification of PLpro inhibitors. Four compounds (F403_0159, F112_0109, G805_0497, D754_0006) with diverse chemical scaffolds were retrieved as hits based on docking score and clustering analysis. Molecular dynamics simulations indicated that the contribution of van der Waals interaction dominated the binding free energies of these compounds, which may be attributed to the hydrophobicity of active site of PLpro from COVID-19. Moreover, all four compounds formed conservative hydrogen bonds with the residues Asp164, Gln269, and Tyr273. We hoped that these four compounds might represent the promising chemical scaffolds for further development of novel PLpro inhibitors against COVID-19.
引用
收藏
页码:879 / 886
页数:7
相关论文
共 171 条
  • [1] Chen Y(2020)Emerging coronaviruses: genome structure, replication, and pathogenesis J Med Virol 92 418-423
  • [2] Liu Q(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 395 497-506
  • [3] Guo D(2020)Insight into 2019 novel coronavirus-an updated interim review and lessons from SARS-CoV and MERS-CoV Int J Infect Dis 94 119-124
  • [4] Huang C(2020)Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China J Med Virol 92 441-447
  • [5] Wang Y(2020)The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak J Autoimmun 109 102433-1207
  • [6] Li X(2020)Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia New Engl J Med 382 1199-13612
  • [7] Ren L(2004)Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity J Virol 78 13600-381
  • [8] Zhao J(2014)SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex Protein & Cell 5 369-3182
  • [9] Hu Y(2015)p53 degradation by a coronavirus papain-like protease suppresses type I interferon signaling J Biol Chem 290 3172-242
  • [10] Zhang L(2016)SARS coronavirus papain-like protease inhibits the TLR7 signaling pathway through removing Lys63-linked polyubiquitination of TRAF3 and TRAF6 Int J Mol Sci 17 678-1688